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Genetic diversity and drug resistance 
surveillance of Plasmodium falciparum 
for malaria elimination: is there an ideal tool 
for resource-limited sub-Saharan Africa?
Tobias O. Apinjoh1, Amed Ouattara2, Vincent P. K. Titanji3, Abdoulaye Djimde4 and Alfred Amambua‑Ngwa5* 
Abstract 
The intensification of malaria control interventions has resulted in its global decline, but it remains a significant public 
health burden especially in sub‑Saharan Africa (sSA). Knowledge on the parasite diversity, its transmission dynamics, 
mechanisms of adaptation to environmental and interventional pressures could help refine or develop new control 
and elimination strategies. Critical to this is the accurate assessment of the parasite’s genetic diversity and monitoring 
of genetic markers of anti‑malarial resistance across all susceptible populations. Such wide molecular surveillance will 
require selected tools and approaches from a variety of ever evolving advancements in technology and the changing 
epidemiology of malaria. The choice of an effective approach for specific endemic settings remains challenging, par‑
ticularly for countries in sSA with limited access to advanced technologies. This article examines the current strategies 
and tools for Plasmodium falciparum genetic diversity typing and resistance monitoring and proposes how the differ‑
ent tools could be employed in resource‑poor settings. Advanced approaches enabling targeted deep sequencing is 
valued as a sensitive method for assessing drug resistance and parasite diversity but remains out of the reach of most 
laboratories in sSA due to the high cost of development and maintenance. It is, however, feasible to equip a limited 
number of laboratories as Centres of Excellence in Africa (CEA), which will receive and process samples from a net‑
work of peripheral laboratories in the continent. Cheaper, sensitive and portable real‑time PCR methods can be used 
in peripheral laboratories to pre‑screen and select samples for targeted deep sequence or genome wide analyses at 
these CEAs.
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Background
Malaria continues to cause significant morbidity and 
mortality across Africa, despite the intensification of 
control interventions [1]. A worldwide decline in its bur-
den was reported in 2015, with rebound and age shift 
in morbidity as control and interventions are scaled up 
[2–6]. Malaria has historically resurged as interventions 
are withdrawn or perturbed by socio-political factors 
[7]. In fact, recent reports suggest that malaria incidence 
increased between 2014 and 2017 in several regions 
across sub-Saharan Africa (sSA), where most of the 
global investments in control and elimination is spent [1]. 
This is a cause for concern and an indication that further 
knowledge on the impact of interventions on parasite and 
vector populations, including parasite’s mechanisms of 
adaptation to environmental and interventional pressures 
are needed to refine control and elimination strategies.
The success of Plasmodium falciparum as a parasite has 
been attributed partly to its enormous genetic diversity 
[8–10], that allows it to adapt to anti-malarials [11] and 
hinder the development of an effective vaccine [12]. Para-
site populations even respond to specific interventions, 
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such as rapid diagnostic tests, human host immune pres-
sure and mosquito vector environment [13–15]. The 
molecular mechanisms and markers of these phenomena 
need to be monitored. Identifying and monitoring mark-
ers of adaptive mechanisms against anti-malarials are of 
particular interest as anti-malarial chemotherapy and 
chemoprophylaxis have been key in reducing mortality 
and morbidity from malaria [16, 17].
Currently, malaria chemotherapy relies mainly on the 
sustained efficacy of artemisinin-based combination 
therapy (ACT), which are the recommended drugs for 
the treatment of adults and children with uncomplicated 
P. falciparum infection [18]. ACT combines artemisinin 
derivatives and other long-acting anti-malarials, with a 
different mechanism of action, to maximize the chances 
of eliminating parasites during treatment, but also to 
limit the possibility of a spontaneous mutation that will 
confer resistance to both drugs [19, 20]. Resistance to 
artemisinin derivatives (ART-R) already emerged and led 
to reduced parasite susceptibility to artemisinin deriva-
tives [21] that manifests as increased parasite clearance 
half-life [22] or persistence of microscopically detectable 
parasites on day 3 post-ACT treatment [19]. Further-
more, ACT resistant P. falciparum, with reduced sus-
ceptibility to both artemisinin derivatives and partner 
drugs, is now a public health concern in South East Asia 
(SEA) [23, 24]. This highlights the parasite’s ability to 
adapt to and successfully evade multiple drug interven-
tions, particularly in SEA. Though the delayed clearance 
phenotype of artemisinin resistance has not been widely 
observed in Africa, continuous surveillance for drug effi-
cacy and molecular markers of resistance provide one 
of the sensitive approaches for early detection of any de 
novo emergence or importation into sSA [25].
Molecular surveillance can help in determining the 
impact of interventions on patterns of genomic variation, 
population structure and gene flow between P. falcipa-
rum from similar or distinct geographical, ecological and 
interventional settings in Africa [26–28]. Molecular epi-
demiology studies also have several implications. Firstly, 
they serve to improve understanding of the parasite’s 
biology and new functional genetic variants can be char-
acterized within and between P. falciparum populations 
[29–31]. Secondly, they can permit the identification of 
novel loci associated with clinically relevant phenotypes 
such as resistance to new and candidate drugs [32, 33]. 
This was recently exemplified following the emergence 
of delayed P. falciparum clearance for artemisinin treat-
ment, where mutations were identified in kelch13 pro-
peller gene (Pfk13) [34] and shown to be spreading 
across SEA [35]. Subsequently, molecular epidemiology 
of variants of kelch13 were employed to time the emer-
gence and evolution of the phenotype across SEA [36, 
37]. Regular monitoring of these markers across malaria 
endemic regions will ensure its containment and prevent 
its emergence or spread to Africa, as was the case with 
previous anti-malarials [38–40]. Beyond the parasite, 
molecular surveillance can be extended to vectors for 
development of tools to monitor and evaluate interven-
tions against the vector, particularly changes in species 
composition, structure and the emergence and spread of 
insecticide resistance [41].
This review aims to examine the current tools for mon-
itoring the emergence of anti-malarial drug resistance 
and the assessment of P. falciparum diversity for malaria 
elimination in sSA. A two-tier approach for widening the 
application of molecular epidemiology into intervention 
approaches is presented; the deployment of the polymer-
ase chain reaction (PCR) and quantitative PCR (qPCR) 
in peripheral laboratories and the application of targeted 
or whole genome sequencing as a sensitive genetic epi-
demiology tool in specialized research centres or Centres 
of Excellence in Africa (CEA). This can be made possi-
ble with new portable PCR machines in the cost range 
USD5000–10,000, which falls within The World Acad-
emy of Science (TWAS) and International Foundation of 
Science (IFS) grants widely accessible to sSA scientists.
Methods
Original peer-reviewed publications were accessed via 
PubMed (www.pubme d.gov) and Google Scholar (www.
googl e.schol ar.com) using the keywords ‘Plasmodium 
falciparum and “genetic diversity” or “anti-malarial drug 
resistance”. In the following sections the authors present 
their findings and suggestions. The variety of approaches 
for drug resistance and diversity monitoring is presented 
in Table 1.
Drug resistance monitoring
To pre-empt the emergence or spread of resistance to 
anti-malarial drugs in Africa, the genotype and pheno-
type of parasites from all malaria endemic populations 
need to be regularly monitored. Accurate molecular sur-
veillance in elimination settings require sensitive diag-
nostics of low grade parasitaemia and unbiased sampling 
strategies that enables resolution of temporal and geo-
spatial patterns. Thus, the detection of parasitaemia by 
histidine rich protein (HRP)-based rapid diagnostic test 
(RDT), for instance, will be insensitive and potentially 
exclude P. falciparum parasites lacking HRP2 and HRP3 
genes [42]. Given available resources, three common 
approaches can provide samples; (a) community-based 
cross-sectional surveys designed to capture the demog-
raphy and spatial specifications of the target popula-
tion, (b) clinical surveys, in which samples from patients 
suspected or diagnosed of malaria at health facilities 
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are collected and (c) therapeutic efficacy studies (TES) 
engaged by research groups or the National Malaria 
Control Programme (NMCP). Each of these sampling 
approaches can be biased by being non-random and 
unrepresentative of the population. This can be amelio-
rated by increasing the density of spatial and temporal 
coverage or analysing all positive samples for populations 
where the prevalence of P. falciparum is low [43].
The choice of drug resistance surveillance assay or 
combination of phenotypic and genotypic analyses 
depends on resources and the primary goal of the study 
and NMCPs [44–47]. Therapeutic efficacy studies remain 
the gold standard for anti-malarial susceptibility test-
ing, but needs significant logistic organization [48]. 
The health budget, infrastructure and trained human 
resources in most sub-Saharan African countries are 
insufficient to support routine and wide application of 
TES. Typically, most NMCPs in sSA are supported by 
World Health Organization (WHO) and/or the Global 
fund for in  vivo TES in limited number of sites. These 
provide samples for PCR correction and global genetic 
surveillance coordinated by the WHO. In  vitro/ex vivo 
testing and genotyping of all tested samples will enrich 
drug efficacy data. Nevertheless, a subset of samples col-
lected either from TES or cross-sectional surveys could 
be analysed by ex vivo/in vitro assays because of logistical 
constrains.
Ex vivo/in vitro tests for resistance
Samples from community or clinical surveys or from 
TES can be tested ex  vivo or in  vitro for susceptibil-
ity to different anti-malarial compounds. In  vitro assays 
assess cultured parasites, meaning that only a subset of 
the parasites collected in the sample that are adapted 
to laboratory culture conditions are analysed, in con-
trast to ex vivo for which fresh samples are immediately 
tested. These drug susceptibility tests offer a convenient 
approach to determine sensitivity to anti-malarials, as 
they are based on direct contact between parasites and 
test drugs over a range of concentrations. In addition, 
several drugs (including those at experimental stages) 
can be tested against the same parasite isolate. A major 
limitation is the need for functional cell culture facilities 
and equipment for measuring parasite growth, such as 
microscope, spectrophotometer, fluorimeter or cytom-
eter. Most tests determine the inhibitory concentration 
that kills half of the cultured parasites (IC50). IC50 assays 
have only recently been standardized by World Wide 
Antimalarial Resistance Network (WWARN) and are not 
suitable for fast acting artemisinin derivatives. Hence, the 
in vitro ring-stage survival assay (RSA) and piperaquine 
survival assay (PSA) were developed for testing ART-
derivatives and piperaquine, respectively [45, 49, 50]. 
RSA together with Pfk13 molecular characterization is 
recommended in surveillance of ART-R [48]. These are 
highly technical assays targeting P. falciparum early ring-
stages with a burst of high drug concentration in  vitro. 
They are also yet to be developed for low grade parasitae-
mia often found in asymptomatic malaria parasite infec-
tion. Like IC50 assays, they are largely unstandardized 
and require specialized cell biology skills and techniques 
to distinguish parasite phenotypes such as dormancy. 
Although it is impossible to standardize in  vitro assays, 
a data analytical tool (IVART) has been developed by 
WWARN to standardize the analyses process and facili-
tate future comparability of data across different studies 
[51]. The lack of drug resistant standards for current and 
candidate drugs, the substantial laboratory infrastructure 
and need for highly trained personnel in cell biology and 
data analysis limits the wide adoption of in  vitro test-
ing across Africa [44]. The future development of short 
culture-independent bench top tests, which target para-
site metabolic markers from pathways of drug resistance, 
could allow for wider adoption.
Genetic markers of anti‑malarial drug resistance
Trends in anti-malarial drug efficacy and resistance can 
also be assessed using molecular markers (Table 2). These 
can be good predictors of treatment outcome patterns at 
a population level [52–54]. Molecular markers have sev-
eral practical advantages over in vitro tests, including the 
possibility of studying many isolates within a short time 
with DNA from dried blood spots (DBS), which are easy 
to collect, transport and store. There exists a wide panel 
of molecular markers, mostly associated with widely 
used previous first line anti-malarial drugs, quinolines 
and sulfadoxine–pyrimethamine (SP) [44]. These previ-
ous first-line drugs are still used for intermittent preven-
tive treatment in pregnancy (IPTp) and seasonal malaria 
chemoprevention (SMC), or against co-transmitted Plas-
modium vivax. Hence, their resistance markers remain 
relevant, especially as some alleles modulate efficacy of 
ACT [55]. Most marker alleles can be typed using tech-
nological variants of various methods, including; dot blot-
ting, restriction fragment length polymorphism (RFLP), 
PCR/qPCR, mini/microarrays, targeted/whole-genome 
sequencing. Sample pooling strategies, advances in PCR 
and DNA sequencing technologies promise to improve the 
scalability of genotyping resistance marker and wider pop-
ulation coverage [56]. Next Generation Sequencing (NGS) 
in particular can now be achieved with as low as $22 per 
Gigabyte (Gb) on Illumina HiSeq 3000/4000 while Third 
Generation Sequencing with Pacific BioSciences, the most 
widely used long-read platform costs $1000 per Gb [57].
Emerging nucleic acid sequencing technologies such 
as the portable nanopore devices also have the potential 
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to revolutionize next-generation sequencing approaches 
towards field-based genotyping in resource-constrained 
regions in sSA. However, nanopore assays specific to 
malaria parasite diversity and drug resistance markers 
are unavailable or only recently been developed despite 
clear applicability of this technology in outbreaks such as 
Ebola and Lassa fever in Africa [58, 59]. Developing field 
deployable assays for markers of ACT component drugs 
(artemisinin derivative in combination with either lume-
fantrine, amodiaquine, mefloquine, quinolines or sulf-
adoxine–pyrimethamine) in Africa would be most useful.
Mutations in the propeller domain of the Pfk13 gene 
have been validated as P. falciparum ART-R markers in 
SEA [34, 54]. SNPs in four other genes, namely, ferre-
doxin (PF3D7_1318100, fd), apicoplast ribosomal pro-
tein S10 (PF3D7_1460900, arps10), multidrug resistance 
protein 2 (mdr2) and chloroquine resistance transporter 
(crt) are also thought to be the backbone loci on which 
ART-R associated kelch13 mutations are most likely to 
arise [54]. Though key Pfk13 ART-R associated muta-
tions are absent in sSA [38], typing panels could include 
known and candidate drug resistance loci whose allele 
frequencies are changing in some parts of sSA follow-
ing ACT implementation [29, 60]. Artemether–lumefan-
trine (AL), for instance, is thought to select for Pfcrt and 
Pfmdr1 wild type variants following treatment. Other 
markers could include variants of Pfap2mu (encoding 
clathrin-associated AP2 adaptor protein, µ subunit) and 
Pfubp1 (encoding ubiquitin carboxyl-terminal hydrolase 
1) found more frequently in P. falciparum isolates post-
ACT [61]. Indeed, candidate SNP variants in Pfap2mu 
should be included in SNP panels for continental surveil-
lance during ACT and for validation as a marker for ACT 
tolerance in African parasite populations.
The choice of genotyping panels is complicated by 
the variety of recommended ACT medicines, het-
erogeneously available across Africa. This presents a 
threat of partner drug resistance across a broad spec-
trum of anti-malarials. Already, mutations in Pfcrt and 
Pfmdr1 are being selected by the most common ACT, 
artemether–lumefantrine (AL) and artesunate–amodi-
aquine (AS–AQ) [62]. Polymorphisms in both genes are 
also associated with structurally similar partner drugs; 
mefloquine, amodiaquine, piperaquine [63]. Moreover, 
Pfcrt mutations as well as plasmepsin 2/3 copy num-
ber variations have been shown to confer P. falciparum 
resistance to piperaquine [64, 65]. The presence of these 
in African populations would affect deployment and effi-
cacy of piperaquine-based ACT [66]. Monitoring of part-
ner drug resistance markers is, therefore, particularly key 
for parasite elimination. When such markers are detected 
in the circulating parasite populations, treatment and 
preventative chemotherapy policy could be revised to 
switch to other drug combinations. Recommended drug-
based preventive malaria interventions in Africa include; 
intermittent preventive treatment in infants (IPTi) and 
pregnant women (IPTp) with SP in areas of moderate-
to-high malaria transmission in sSA and amodiaquine in 
Table 2 Mode of  action, targets and  resistance mechanisms of  drugs for  P. falciparum malaria treatment and  control 
in sSA
Recommended ACTs for treatment of malaria have artemisinin or its derivative combined with one or more drugs and include: AL, AS–AQ, AS–MQ, AS–SP and DHA–
PPQ. As of 2016, most African countries use AL and AS–AQ, with some adding DHA–PPQ for uncomplicated malaria, AS, AM and QN for severe malaria and SP for IPTp 
(1)
CNV copy number variation, Pfmrp-1 P. falciparum multi-resistance protein 1 gene, Pfnhe-1 P. falciparum  Na+/H+ exchanger-1, Pfmdt P. falciparum metabolic drug 
transporter, PftetQ P. falciparum tet Q GTPase
Drugs Mode of action Molecular markers of resistance Resistance mechanism
Artemether (AM) Not well understood, oxidative dam‑
age to proteins and lipids and/or 
targeting the phosphatidylinositol‑
3‑kinase (PfPI3K)
Pfk13, Pfmdr‑1, Pfmrp‑1 Not clearly understood; SNPs, CNVs
Artesunate (AS)
Dihydroartemisinin (DHA)
Pyrimethamine Inhibits folic acid synthesis Pfdhfr SNPs
Sulphadoxine Pfdhps SNPs
Amodiaquine (AQ), lumefantrine (LM) Inhibits haem detoxification Pfcrt SNPs
Pfmdr‑1 SNPs
Mefloquine (MQ) CNVs
Pfcrt, plasmepsin 2/3 SNPs, CNVs
Quinine (QN) Pfmdr‑1, Pfcrt, Pfmrp‑1, Pfnhe‑1 SNPs
Piperaquine (PPQ) Inhibits haem detoxification, inhibits 
one or more steps in the haemoglo‑
bin degradation
Clindamycin Inhibits protein synthesis Pfmdt, PftetQ CNVs
Doxycycline
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combination with SP for SMC in the Sahel [16, 67]. How-
ever, resistance to SP is widespread and marked by muta-
tions in the P. falciparum dihydropteroate synthetase 
(Pfdhps) and dihydrofolate reductase (Pfdhfr) genes. 
Though chloroquine, amodiaquine and SP are no longer 
first-line malaria treatment, mutations in Pfmdr1, Pfdhfr, 
Pfdhps, Pfcrt and candidate loci for artemisinin and pipe-
raquine resistance are needed to assess the impact of cur-
rent drug interventions.
The design of surveillance panels should consider the 
complex relationships between individual mutations and 
haplotypes with sensitivity to specific anti-malarials. For 
instance, the Pfcrt 76T mutant is essential for chloro-
quine resistance but is selected as Pfcrt CVIET or Pfcrt 
SVMNT haplotypes that confer fitness against chloro-
quine pressure [68]. Similarly, SP resistance is linked to 
the Pfdhfr IRN triple and Pfdhps double GE haplotypes 
selected by SP interventions [69]. Medium SNP typ-
ing panels could include these linked loci, while small 
panels could combine markers that maximize informa-
tion for key resistance loci of anti-malarial treatments 
or chemoprevention. For example, countries using AL, 
could employ a small panel consisting of N86Y, K76T 
and C580Y for Pfmdr1, Pfcrt and Pfk13, respectively. This 
can be expanded to include Pfdhfr K540E and A581G to 
cover selection by IPTi/IPTp and SMC in the Sahel. These 
panels will gain from assays such as RFLP and allelic dis-
crimination real time PCR by high resolution melting 
(HRM), which do not rely on heavy and expensive equip-
ment. These techniques can achieve higher coverage 
given the wide availability of restriction and amplification 
reagents including isothermal polymerases. They could 
be extended to detect copy number variants, such as 
those in plasmepsin genes associated with sensitivity to 
piperaquine. The small/medium panels would be used at 
peripheral labs with limited capabilities, but all the mark-
ers should be assessed in CEAs.
Parasite diversity monitoring
Single nucleotide polymorphisms and structural genetic 
variants of P. falciparum can serve to fingerprint infect-
ing parasites and inform the effectiveness of drug treat-
ments or vector interventions. Four major strategies have 
mostly been explored, each with advantages and limita-
tions for wide adoption across sSA. These include: msp/
glurp typing, microsatellite analysis, molecular (DNA) 
barcodes, targeted deep sequencing and genome-wide 
variation analysis.
msp/glurp typing
Viriyakosol et al. [70] were the first to deploy a tool that 
exploits length polymorphisms in merozoite surface pro-
tein (msp) and glutamine rich protein (glurp) genes to 
assess the identity or genotype of infecting parasites. Two 
different msp markers are often used, msp1 and 2. This 
technique is particularly useful in determining the com-
plexity of infection (COI), a measure of the effectiveness 
of intervention programmes. Msp/glurp typing are widely 
used in anti-malarial drug efficacy trials to distinguish-
ing recrudescent parasites from new infections [71, 72]. 
It has been one of the most widely adopted techniques 
because of the availability of PCR and DNA electropho-
resis equipment which are now portable. Furthermore, 
its sensitivity and reliability are improved in specialized 
laboratories by incorporating capillary electrophoresis 
and more recently qPCR-HRM [71, 73].
A major limitation of msp/glurp typing is lack of 
standardization of scoring and reporting formats that 
can allow for the comparison of results across different 
endemic site laboratories. The msp/glurp genotyping pro-
tocol is also labour-intensive, depends on the sensitivity 
of PCR, which may not amplify low abundance variants 
or result in artefacts [74]. In addition, the sensitivity is 
low when using agarose gels and the interpretation can 
be subjective, especially in high transmission areas in 
Africa where polyclonal infections will lead to multiple 
bands. Furthermore, msp/glurp genes are under immune 
selection pressure, which can skew the frequency of some 
allelotypes [30]. This could affect the accuracy of popu-
lation structure and transmission patterns inferred from 
these loci. Notwithstanding the above limitations of msp/
glurp typing, it remains a popular method for fingerprint-
ing across endemic regions in sSA. Its continuous use will 
benefit from allele size reference standards derived from 
culture adapted reference isolates from major P. falcipa-
rum populations across Africa.
Microsatellite analysis
Microsatellites are tandem repeats of one to six base 
pairs (bp) that are highly polymorphic. They are abun-
dant in the P. falciparum genome, mainly as [TA]n, [T]
n, and [TAA]n repeats [75]. Anderson and colleagues 
pioneered assays of twelve microsatellite loci as sensi-
tive tools for parasite genetic structure and differen-
tiation analyses [76]. These twelve loci have been widely 
used for assessment of genetic diversity and population 
structure across many studies. In the context of malaria 
elimination, microsatellites can be used to fingerprint 
parasites and resolve relatedness of infections at high 
spatial resolutions especially in settings with low preva-
lence and high levels of monoclonality [77–79]. Also, the 
combination of P. falciparum drug-resistance markers 
and flanking microsatellite loci can be employed to assess 
the genetic diversity and evolution of selective signatures 
around drug resistance genes [39].
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Similar to msp/glurp typing, microsatellite typing 
depends on accurate DNA fragment amplification by 
PCR, which can result in artefacts. Accurate allele sizing 
requires expensive capillary electrophoresis equipment 
that are largely unavailable. Moreover, there are no meth-
ods for phase resolution of parasite haplotypes in mixed 
infections. However, thousands of P. falciparum genome 
sequences are now available for mining new microsat-
ellite loci which can be developed into new assays for 
population diversity analyses. Low cost thermocyclers 
combined with HRM for determining sizes of DNA frag-
ments can improve the availability of microsatellite typ-
ing to less specialized laboratories [80].
Molecular (DNA) barcodes
SNP barcoding has been shown to be robust for evalu-
ating parasite genotypes derived from communities, 
malaria patients or laboratory strains [81]. It provides a 
fingerprint for each infection, distinguishing the hap-
lotype signature for single clone infections from those 
with mixtures of parasite genomes [82]. SNP barcod-
ing are also sensitive for detecting and genotyping 
sub-microscopic parasitaemia in low malaria transmis-
sion areas even when RDTs are negative [83]. In addi-
tion, the technique has the potential for identifying the 
sources of epidemics [84]. The choice of a SNP panel 
and density within a barcode can be guided by the level 
of sensitivity required for distinguishing populations 
or detecting alleles associated with phenotypes such as 
drug resistance. Early approaches were based on qPCR 
to distinguish alleles of a panel of 24 SNPs that repre-
sented unique signatures for P. falciparum isolates [82]. 
These panels have been developed for qPCR-HRM and 
the Sequenom Mass Array assays [84, 85]. Only a small 
number of specialized labs in Africa have successfully 
implemented and used these assays due to the absence 
and cost of advanced PCR or array technologies. Several 
other SNP barcode combinations have now been devel-
oped for different types of analyses:
 I. A 96 genome-wide SNP panel used to assess the 
impact of decreased transmission on parasite 
diversity in Senegal and at the Thai-Burma border 
[79, 86]. These findings revealed increasingly clonal 
infections (identical genotypes), due to increased 
selfing and reduced multilocus recombination as 
populations declined.
 II. A 384-SNP custom GoldenGate Illumina Mass 
array that clearly resolved global patterns of genetic 
diversity and the structure of geographically dis-
tinct populations across global endemic popula-
tions [85].
 III. 23-SNP panel for P. falciparum containing five 
mitochondrial and 18 SNPs of the apicoplast 
genomes thought to offer a higher resolution 
between isolates from different endemic blocs [87]. 
The fact that the organelle genome is refractory to 
recombination makes the mitochondrian/apico-
plast SNP panel ideal for mapping the geographic 
origin of P. falciparum isolates. This can identify 
imported cases of P. falciparum into elimination 
settings.
 IV. A recent malaria Taqman Array with 87 loci that 
enable both species classification and typing of 
markers across drug resistance and neutral loci 
[88]. Deployment will be limited by access to the 
viiA7™ real-time PCR machine. Centres without 
sequencing and Mass Array facilities can consider 
this as a viable option for simultaneous drug resist-
ance and diversity typing upon the added benefit of 
species detection in mixed infections.
 V. The Spot malaria project currently provides a large 
panel of loci including targets for drug resistance 
and neutral sites for population diversity analysis. 
This has been constituted into a ‘Genetic Report 
Card’ (GenRE). This will become increasingly use-
ful as the genotyping methods applied are sensitive 
enough to detect parasites genomes and alleles in 
very low-density infections (https ://www.malar 
iagen .net/proje cts/spotm alari a).
While the above techniques and platforms overcome 
the limitations of traditional msp/glurp and microsatel-
lite genotyping, they remain mostly applicable only in 
specialized northern labs. Furthermore, their sensitiv-
ity across populations of different effective sizes and 
recombination rates, which disrupts association among 
SNPs panel, remain unevaluated. These techniques are 
also most suitable for single clone infections. Even with 
the application of algorithms such as RealMcCOIL to 
estimate the number of infecting genomes in mixed 
infections, reconstruction and analysis of individual 
haplotypes from infections with greater than two clones 
remain almost impossible [89]. With thousands of P. falci-
parum genomes now available, new barcode panels with 
population specific alleles combined with new computa-
tional models should allow for high resolution determi-
nation of origin and diversity of infections in elimination 
settings and connectivity between spatial transmission 
hotspots.
Targeted deep sequencing (TDS)
This is a powerful approach for variant discovery and 
detection in target genes or genomic regions. TDS can 
assess the relative distribution of variants of specific 
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genes at individual patient level, or at population level 
with variance in environment; heterogeneous human 
and vector hosts as well as interventions. Coupled to 
long read technologies, it can also permit the reconstruc-
tion of haplotypes for relevant genes such as drug resist-
ance loci and vaccine candidates. Applied to known or 
candidate drug resistance gene loci, it can elucidate the 
landscape of selection of alleles in such targets as para-
sites adapt against drugs [90]. In an observational surveil-
lance study of potential drug resistance loci in Senegal 
and Thailand, TDS identified dozens of previously unde-
scribed mutations in Pfk13 [91, 92]. TDS can, therefore, 
be an important public health tool, enabling the detec-
tion of low frequency and potential drug resistance loci 
that may be selected under increased drug pressure.
TDS of P. falciparum also provides a high-throughput, 
highly sensitive approach for detecting minority clones 
in polyclonal infections and more accurate quantitative 
estimates of clonal frequency [10, 93]. By determining 
the frequency of parasite gene haplotypes in individual 
infections from a parasite population, the tool can ena-
ble the assessment of within-host diversity, recombina-
tion events and relatedness between infections. Such 
applications are important in the context of Africa where 
infections are often mixed, and the ecology of mixed gen-
otypes might influence the transmission of drug resist-
ance loci, the backbone on which resistance may emerge 
or clones selected by vaccines [94]. However, TDS suf-
fers from ascertainment bias of gene panels. It requires 
next-generation sequencers, powerful computation and 
well-trained biostatisticians for data analysis that are not 
readily available in malaria endemic countries. As this 
can produce highly relevant data for diversity and drug 
resistance monitoring in elimination settings, central-
ized analyses can be done at CEAs and dissemination of 
simplified reports such as heatmaps of allele and haplo-
type frequencies could facilitate translation by control 
programmes.
Genome‑wide variation analysis (GVA)
Global surveys of P. falciparum genomic variations 
has revealed thousands of SNPs, indels, and struc-
tural variants, typed across populations using microar-
ray or next-generation sequencing approaches [10, 31]. 
Genome-wide SNP loci have mostly been character-
ized and used to scan for and differentiate signatures of 
natural selection or employed in genome-wide associa-
tion studies to identify loci underlying phenotypes such 
as drug resistance [25, 30, 32, 33]. Genome-wide varia-
tion typing has evolved from microarray technologies, 
which suffer from ascertainment bias, to whole genome 
sequencing (WGS) by short read technologies. Theo-
retically, the wide variety and density of polymorphisms 
from WGS should improve the resolution of studies on 
diversity, the tracking of known functional variants and 
discovery of novel markers that may be associated with 
new adaptive parasite phenotypes. WGS data can also be 
employed in development of new population genetic and 
diagnostic tools.
Unlike the analysis of individual loci, which may be 
the target of strong natural selection, inferences from 
genome-wide diversity are less subject to target biases 
and, therefore, more accurately reflect overall patterns of 
P. falciparum genetic variation. Nevertheless, the current 
costs of next-generation sequencers, sample processing 
reagents, infrastructure for data storage and analysis and 
need for trained lab and data analyses scientists limits its 
wide application across most of Africa. In addition, WGS 
may be limited by the lack of good quality DNA and 
the need for enrichment for blood samples that contain 
mostly human DNA. Furthermore, it is difficult to con-
struct haplotypes for complex infections and the tech-
nique has a low sensitivity to detect minority clones. With 
improved error rates from cheaper portable sequencers, 
such as the nanopore, WGS and GVA will most likely 
become more translational for malaria elimination. A 
model where a limited number of CEA laboratories can 
be equipped to receive and process samples from a net-
work of peripheral laboratories in the continent at high 
throughput is proposed. Already, WGS is possible in a 
number of centres in sSA such as the Medical Research 
Council Unit The Gambia at LSHM. Human capacity 
for bioinformatics is also being built through African-
led networks; Developing Excellence in Leadership and 
Genetics Training for Malaria Elimination (DELGEME, 
www.delge me.org) and the Human Hereditary and dis-
ease in Africa (H3Africa) Pan-African Genetic Epide-
miology Network (PAMGEN). These programmes will 
expand access and application of WGS/GVA approaches 
to malaria elimination research in sSA. Effective deploy-
ment and translation could be further facilitated by sam-
ple pooling and employing cheaper but sensitive Real 
time PCR genotyping methods to pre-screen and select 
samples in peripheral laboratories prior to genome wide 
analyses at CEAs. Pre-screening could prioritize loci for 
diversity, drug or vaccine resistance most relevant to the 
local control and intervention strategies.
Conclusion
Genetic epidemiology of malaria can improve under-
standing of parasite origins, flow rates between popu-
lations (temporal and spatial), drug resistance and 
potential susceptibility to candidate anti-malarial drugs 
and vaccines [26, 29, 95, 96]. Current knowledge on 
parasite molecular epidemiology has mostly been gen-
erated by research with little contribution or guidance 
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from control programmes. This is partly due to limited 
resources for accessing molecular genotyping technolo-
gies and genetic data as a strategy to guide policy, espe-
cially in Africa. As it is now clear that malaria parasites 
deploys their enormous genetic diversity to fight against 
interventions and host immunity, wider surveys and 
analyses of parasite genetic variation across different 
populations will facilitate population specific interven-
tions and provide information to contain resurgence [97]. 
The tools for generating these genetic data are varied by 
cost, technological complexity and sensitivity for single 
nucleotide typing, fingerprinting barcodes, microsatel-
lites, targeted gene variants and whole genome polymor-
phisms. The choice of the strategy however will depend 
on the objectives and resources at the disposal of scien-
tists and NMCPs.
Targeted deep and whole genome sequencing are 
sensitive and specific for detecting patterns of malaria 
parasite diversity and critical for ‘drug resistant intel-
ligence’. Though they required significant investment 
in equipment and trained personnel, it is feasible to 
equip genomic Centres of Excellence in Africa, which 
will receive and process samples from a network of 
smaller laboratories with PCR capabilities. These cen-
tres will be hubs for developing field deployable geno-
typing assays for PCR and portable next-Generation 
sequencing technologies such as the Nanopore to boost 
genomic surveillance for malaria elimination in Africa. 
Centres of excellence and molecular surveillance nodes 
will need computational infrastructure to combine novel 
approaches for ancestry, relatedness, transmission mod-
els and machine learning to resolve spatial–temporal 
parasite flow, population structure and drug resistance 
[98, 99]. Thus, genetic epidemiology consortia that inte-
grate with NMCPs, such as the Plasmodium Diversity 
Network Africa (PDNA) and its training programme for 
data analysis (DELGEME) represent excellent models for 
networking and building capacity in sSA for genomics to 
track and monitor malaria elimination [100].
Abbreviations
sSA: sub‑Saharan Africa; CEA: Centres of Excellence in Africa; ACT : artemisinin‑
based combination therapy; ART‑R: resistance to artemisinin derivatives; SEA: 
South East Asia; PCR: polymerase chain reaction; qPCR: quantitative PCR; HRM: 
high resolution melting; TWAS: The World Academy of Science; IFS: Interna‑
tional Foundation of Science; HRP: histidine‑rich protein; RDT: rapid diagnostic 
test; TES: therapeutic efficacy studies; NMCP: National Malaria Control Pro‑
gramme; WHO: World Health Organization; IC50: inhibitory concentration that 
kills half of the cultured parasites; WWARN: World Wide Antimalarial Resistance 
Network; SMC: seasonal malaria chemoprevention; IPTp: intermittent preven‑
tive treatment in pregnancy; RFLP: restriction fragment length polymorphism; 
NGS: next generation sequencing; Gb: gigabyte; AL: artemether–lumefantrine; 
AS–AQ: artesunate–amodiaquine; MSP: merozoite surface protein; GLURP: glu‑
tamine rich protein; COI: complexity of infection; TDS: targeted deep sequenc‑
ing; GVA: genome‑wide variation analysis; WGS: whole genome sequencing; 
DELGEME: Developing Excellence in Leadership and Genetics Training for 
Malaria Elimination in sub‑Saharan Africa; PAMGEN: Pan‑African Genetic 
Epidemiology Network; PDNA: Plasmodium Diversity Network Africa; AESA: 
Alliance for Accelerating Excellence in Science in Africa; AAS: African Academy 
of Sciences; Pfk13: P. falciparum kelch13 propeller gene; Pfcrt: P. falciparum 
chloroquine resistance transporter; Pfmdr1: P. falciparum multidrug resist‑
ance protein 1; Pfmdr2: P. falciparum multidrug resistance protein 2; Pfubp1: 
P. falciparum ubiquitin carboxyl‑terminal hydrolase 1; Pfap2mu: P. falciparum 
clathrin‑associated AP2 adaptor, µ subunit; Pfdhfr: P. falciparum dihydrofolate 
reductase; Pfdhps: P. falciparum dihydropteroate synthetase.
Acknowledgements
This work was supported through the DELTAS Africa Initiative (DELGEME 
grant 107740/Z/15/Z). The DELTAS Africa Initiative is an independent funding 
scheme of the African Academy of Sciences (AAS)’s Alliance for Accelerating 
Excellence in Science in Africa (AESA) and supported by the New Partnership 
for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) 
with funding from the Wellcome Trust (DELGEME grant 107740/Z/15/Z) and 
the UK government. The views expressed in this publication are those of the 
author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust, or 
the UK government.
Authors’ contributions
The initial draft was done by TOA. The other authors revised and made intel‑
lectual inputs into the manuscript. All authors read and approved the final 
manuscript.
Funding
This work was supported by the Developing Excellence in Leadership and 
Genetics Training for Malaria Elimination in sub‑Saharan Africa (DELGEME) 
program (Grant 107740/Z/15/Z) sponsored by the Developing Excellence in 
Leadership, Training, and Science (DELTAS) Africa initiative.
Availability of data and materials
Not applicable.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1 Department of Biochemistry and Molecular Biology, University of Buea, 
Buea, Cameroon. 2 School of Medicine, University of Maryland, College Park, 
Baltimore, USA. 3 Faculty of Science, Engineering and Technology, Cameroon 
Christian University, Bali, Cameroon. 4 Malaria Research and Training Centre, 
University of Science, Techniques and Technologies of Bamako, Bamako, Mali. 
5 Medical Research Council Unit The Gambia at LSHTM, Banjul, The Gambia. 
Received: 26 September 2018   Accepted: 18 June 2019
References
 1. WHO. World malaria report 2018. Geneva: World Health Organization; 
2018.
 2. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, 
et al. The effect of malaria control on Plasmodium falciparum in Africa 
between 2000 and 2015. Nature. 2015;526:207211.
 3. WHO. World malaria report 2016. Geneva: World Health Organization; 
2016.
 4. Apinjoh TO, Anchang‑Kimbi JK, Mugri RN, Tangoh DA, Nyingchu RV, 
Chi HF, et al. The effect of insecticide treated nets (ITNs) on Plasmodium 
falciparum infection in rural and semi‑urban communities in the south 
west region of Cameroon. PLoS ONE. 2015;10:e0116300.
Page 10 of 12Apinjoh et al. Malar J          (2019) 18:217 
 5. Griffin JT, Ferguson NM, Ghani AC. Estimates of the changing age‑
burden of Plasmodium falciparum malaria disease in sub‑Saharan Africa. 
Nat Commun. 2014;5:3136.
 6. Trape JF, Tall A, Diagne N, Ndiath O, Ly AB, Faye J, et al. Malaria morbidity 
and pyrethroid resistance after the introduction of insecticide‑treated 
bednets and artemisinin‑based combination therapies: a longitudinal 
study. Lancet Infect Dis. 2011;11:925–32.
 7. Cohen JM, Smith DL, Cotter C, Ward A, Yamey G, Sabot OJ, et al. Malaria 
resurgence: a systematic review and assessment of its causes. Malar J. 
2012;11:122.
 8. Neafsey DE, Schaffner SF, Volkman SK, Park D, Montgomery P, Milner DA 
Jr, et al. Genome‑wide SNP genotyping highlights the role of natural 
selection in Plasmodium falciparum population divergence. Genome 
Biol. 2008;9:R171.
 9. Volkman SK, Sabeti PC, DeCaprio D, Neafsey DE, Schaffner SF, Milner DA 
Jr, et al. A genome‑wide map of diversity in Plasmodium falciparum. Nat 
Genet. 2007;39:113–9.
 10. Manske M, Miotto O, Campino S, Auburn S, Almagro‑Garcia J, Maslen G, 
et al. Analysis of Plasmodium falciparum diversity in natural infections 
by deep sequencing. Nature. 2012;487:375–9.
 11. Ekland EH, Fidock DA. Advances in understanding the genetic basis of 
antimalarial drug resistance. Curr Opin Microbiol. 2007;10:363–70.
 12. Takala SL, Plowe CV. Genetic diversity and malaria vaccine design, test‑
ing and efficacy: preventing and overcoming ‘vaccine resistant malaria’. 
Parasite Immunol. 2009;31:560–73.
 13. Watson OJ, Slater HC, Verity R, Parr JB, Mwandagalirwa MK, Tshefu A, 
et al. Modelling the drivers of the spread of Plasmodium falciparum 
hrp2 gene deletions in sub‑Saharan Africa. Elife. 2017;6:e25008.
 14. Molina‑Cruz A, Canepa GE, Kamath N, Pavlovic NV, Mu J, Ramphul 
UN, et al. Plasmodium evasion of mosquito immunity and global 
malaria transmission: the lock‑and‑key theory. Proc Natl Acad Sci USA. 
2015;112:15178–83.
 15. Gomes PS, Bhardwaj J, Rivera‑Correa J, Freire‑De‑Lima CG, Morrot 
A. Immune escape strategies of malaria parasites. Front Microbiol. 
2016;7:1617.
 16. WHO. Seasonal malaria chemoprevention (SMC) for Plasmodium 
falciparum malaria control in highly seasonal transmission areas of the 
Sahel sub‑region in Africa. Geneva: World Health Organization; 2012.
 17. WHO, Global Malaria Programme. The role of mass drug administration, 
mass screening and treatment, and focal screening and treatment for 
malaria: recommendations. Geneva: World Health Organization; 2015.
 18. WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World 
Health Organization; 2015.
 19. WHO. Global report on antimalarial efficacy and drug resistance: 
2000–2010. Geneva: World Health Organization; 2010.
 20. Nosten F, White NJ. Artemisinin‑based combination treatment of falci‑
parum malaria. Am J Trop Med Hyg. 2007;77:181–92.
 21. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Arte‑
misinin resistance in Plasmodium falciparum malaria. N Engl J Med. 
2009;361:455–67.
 22. White NJ. The parasite clearance curve. Malar J. 2011;10:278.
 23. Na‑Bangchang K, Muhamad P, Ruaengweerayut R, Chaijaroenkul W, 
Karbwang J. Identification of resistance of Plasmodium falciparum to 
artesunate–mefloquine combination in an area along the Thai‑Myan‑
mar border: integration of clinico‑parasitological response, systemic 
drug exposure, and in vitro parasite sensitivity. Malar J. 2013;12:263.
 24. Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, et al. Dihydroar‑
temisinin–piperaquine resistance in Plasmodium falciparum malaria 
in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 
2016;16:357–65.
 25. Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, et al. 
Genetic markers associated with dihydroartemisinin–piperaquine 
failure in Plasmodium falciparum malaria in Cambodia: a genotype‑
phenotype association study. Lancet Infect Dis. 2017;17:164–73.
 26. Omedo I, Mogeni P, Rockett K, Kamau A, Hubbart C, Jeffreys A, et al. 
Geographic‑genetic analysis of Plasmodium falciparum parasite 
populations from surveys of primary school children in Western Kenya. 
Wellcome Open Res. 2017;2:29.
 27. Dwivedi A, Khim N, Reynes C, Ravel P, Ma L, Tichit M, et al. Plasmodium 
falciparum parasite population structure and gene flow associated to 
anti‑malarial drugs resistance in Cambodia. Malar J. 2016;15:319.
 28. Babiker HA, Walliker D. Current views on the population structure 
of Plasmodium falciparum: implications for control. Parasitol Today. 
1997;13:262–7.
 29. Amambua‑Ngwa A, Jeffries D, Amato R, Worwui A, Karim M, Ceesay S, 
et al. Consistent signatures of selection from genomic analysis of pairs 
of temporal and spatial Plasmodium falciparum populations from The 
Gambia. Sci Rep. 2018;8:9687.
 30. Amambua‑Ngwa A, Tetteh KK, Manske M, Gomez‑Escobar N, Stewart 
LB, Deerhake ME, et al. Population genomic scan for candidate 
signatures of balancing selection to guide antigen characterization in 
malaria parasites. PLoS Genet. 2012;8:e1002992.
 31. Amambua‑Ngwa A, Park DJ, Volkman SK, Barnes KG, Bei AK, Lukens AK, 
et al. SNP genotyping identifies new signatures of selection in a deep 
sample of West African Plasmodium falciparum malaria parasites. Mol 
Biol Evol. 2012;29:3249–53.
 32. Van Tyne D, Park DJ, Schaffner SF, Neafsey DE, Angelino E, Cortese JF, 
et al. Identification and functional validation of the novel antimalarial 
resistance locus PF10_0355 in Plasmodium falciparum. PLoS Genet. 
2011;7:e1001383.
 33. Park DJ, Lukens AK, Neafsey DE, Schaffner SF, Chang HH, Valim C, et al. 
Sequence‑based association and selection scans identify drug resist‑
ance loci in the Plasmodium falciparum malaria parasite. Proc Natl Acad 
Sci USA. 2012;109:13052–7.
 34. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, 
et al. A molecular marker of artemisinin‑resistant Plasmodium falcipa-
rum malaria. Nature. 2014;505:50–5.
 35. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. 
Spread of artemisinin resistance in Plasmodium falciparum malaria. N 
Engl J Med. 2014;371:411–23.
 36. Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, 
et al. The spread of artemisinin‑resistant Plasmodium falciparum in the 
Greater Mekong subregion: a molecular epidemiology observational 
study. Lancet Infect Dis. 2017;17:491–7.
 37. Takala‑Harrison S, Jacob CG, Arze C, Cummings MP, Silva JC, Dondorp 
AM, et al. Independent emergence of artemisinin resistance muta‑
tions among Plasmodium falciparum in Southeast Asia. J Infect Dis. 
2015;211:670–9.
 38. Kamau E, Campino S, Amenga‑Etego L, Drury E, Ishengoma D, Johnson 
K, et al. K13‑propeller polymorphisms in Plasmodium falciparum para‑
sites from sub‑Saharan Africa. J Infect Dis. 2015;211:1352–5.
 39. Wootton JC, Feng X, Ferdig MT, Cooper RA, Mu J, Baruch DI, et al. 
Genetic diversity and chloroquine selective sweeps in Plasmodium 
falciparum. Nature. 2002;418:320–3.
 40. Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T. Intercontinen‑
tal spread of pyrimethamine‑resistant malaria. Science. 2004;305:1124.
 41. Donnelly MJ, Isaacs AT, Weetman D. Identification, validation, and 
application of molecular diagnostics for insecticide resistance in malaria 
vectors. Trends Parasitol. 2016;32:197–206.
 42. Baker J, Ho MF, Pelecanos A, Gatton M, Chen N, Abdullah S, et al. Global 
sequence variation in the histidine‑rich proteins 2 and 3 of Plasmodium 
falciparum: implications for the performance of malaria rapid diagnostic 
tests. Malar J. 2010;9:129.
 43. WHO. Malaria surveillance, monitoring & evaluation: a reference 
manual. Geneva: World Health Organization; 2018.
 44. Nsanzabana C, Djalle D, Guerin PJ, Menard D, Gonzalez IJ. Tools for sur‑
veillance of anti‑malarial drug resistance: an assessment of the current 
landscape. Malar J. 2018;17:75.
 45. Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, et al. 
Novel phenotypic assays for the detection of artemisinin‑resistant 
Plasmodium falciparum malaria in Cambodia: in vitro and ex vivo drug‑
response studies. Lancet Infect Dis. 2013;13:1043–9.
 46. Plowe CV. Antimalarial drug resistance in Africa: strategies for monitor‑
ing and deterrence. Curr Top Microbiol Immunol. 2005;295:55–79.
 47. Plowe CV. Monitoring antimalarial drug resistance: making the most of 
the tools at hand. J Exp Biol. 2003;206:3745–52.
 48. WHO. Tools for monitoring antimalarial drug efficacy. Geneva: World 
Health Organization; 2019.
 49. Kite WA, Melendez‑Muniz VA, Moraes Barros RR, Wellems TE, Sa JM. 
Alternative methods for the Plasmodium falciparum artemisinin ring‑
stage survival assay with increased simplicity and parasite stage‑speci‑
ficity. Malar J. 2016;15:94.
Page 11 of 12Apinjoh et al. Malar J          (2019) 18:217 
 50. Duru V, Khim N, Leang R, Kim S, Domergue A, Kloeung N, et al. 
Plasmodium falciparum dihydroartemisinin–piperaquine failures in 
Cambodia are associated with mutant K13 parasites presenting high 
survival rates in novel piperaquine in vitro assays: retrospective and 
prospective investigations. BMC Med. 2015;13:305.
 51. Woodrow CJ, Dahlstrom S, Cooksey R, Flegg JA, Le Nagard H, Mentre 
F, et al. High‑throughput analysis of antimalarial susceptibility 
data by the WorldWide Antimalarial Resistance Network (WWARN) 
in vitro analysis and reporting tool. Antimicrob Agents Chemother. 
2013;57:3121–30.
 52. Bushman M, Morton L, Duah N, Quashie N, Abuaku B, Koram KA, et al. 
Within‑host competition and drug resistance in the human malaria 
parasite Plasmodium falciparum. Proc Biol Sci. 2016;283:20153038.
 53. Marfurt J, Muller I, Sie A, Oa O, Reeder JC, Smith TA, et al. The useful‑
ness of twenty‑four molecular markers in predicting treatment 
outcome with combination therapy of amodiaquine plus sulfadox‑
ine–pyrimethamine against falciparum malaria in Papua New Guinea. 
Malar J. 2008;7:61.
 54. Miotto O, Amato R, Ashley EA, MacInnis B, Almagro‑Garcia J, 
Amaratunga C, et al. Genetic architecture of artemisinin‑resistant 
Plasmodium falciparum. Nat Genet. 2015;47:226–34.
 55. Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gnadig N, Uhlemann AC, 
et al. Globally prevalent PfMDR1 mutations modulate Plasmodium 
falciparum susceptibility to artemisinin‑based combination therapies. 
Nat Commun. 2016;7:11553.
 56. Taylor SM, Parobek CM, Aragam N, Ngasala BE, Martensson A, Mesh‑
nick SR, et al. Pooled deep sequencing of Plasmodium falciparum 
isolates: an efficient and scalable tool to quantify prevailing malaria 
drug‑resistance genotypes. J Infect Dis. 2013;208:1998–2006.
 57. Goodwin S, McPherson JD, McCombie WR. Coming of age: ten 
years of next‑generation sequencing technologies. Nat Rev Genet. 
2016;17:333–51.
 58. Runtuwene LR, Tuda JSB, Mongan AE, Makalowski W, Frith MC, 
Imwong M, et al. Nanopore sequencing of drug‑resistance‑asso‑
ciated genes in malaria parasites, Plasmodium falciparum. Sci Rep. 
2018;8:8286.
 59. Quick J, Loman NJ, Duraffour S, Simpson JT, Severi E, Cowley L, et al. 
Real‑time, portable genome sequencing for Ebola surveillance. Nature. 
2016;530:228–32.
 60. Achieng AO, Muiruri P, Ingasia LA, Opot BH, Juma DW, Yeda R, et al. Tem‑
poral trends in prevalence of Plasmodium falciparum molecular markers 
selected for by artemether–lumefantrine treatment in pre‑ACT and 
post‑ACT parasites in western Kenya. Int J Parasitol Drugs Drug Resist. 
2015;5:92–9.
 61. Henriques G, Hallett RL, Beshir KB, Gadalla NB, Johnson RE, Burrow R, 
et al. Directional selection at the pfmdr1, pfcrt, pfubp1, and pfap2mu 
loci of Plasmodium falciparum in Kenyan children treated with ACT. J 
Infect Dis. 2014;210:2001–8.
 62. Okell LC, Reiter LM, Ebbe LS, Baraka V, Bisanzio D, Watson OJ, et al. 
Emerging implications of policies on malaria treatment: genetic 
changes in the Pfmdr‑1 gene affecting susceptibility to artemether–
lumefantrine and artesunate–amodiaquine in Africa. BMJ Glob Health. 
2018;3:e000999.
 63. Nsanzabana C. Resistance to artemisinin combination therapies (ACTs): 
do not forget the partner drug! Trop Med Infect Dis. 2019;4:e26.
 64. Ross LS, Dhingra SK, Mok S, Yeo T, Wicht KJ, Kumpornsin K, et al. Emerg‑
ing Southeast Asian PfCRT mutations confer Plasmodium falciparum 
resistance to the first‑line antimalarial piperaquine. Nat Commun. 
2018;9:3314.
 65. Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, et al. 
A surrogate marker of piperaquine‑resistant Plasmodium falciparum 
malaria: a phenotype‑genotype association study. Lancet Infect Dis. 
2017;17:174–83.
 66. Inoue J, Silva M, Fofana B, Sanogo K, Martensson A, Sagara I, et al. 
Plasmodium falciparum plasmepsin 2 duplications, West Africa. Emerg 
Infect Dis. 2018;24:8.
 67. WHO. Intermittent preventive treatment in pregnancy (IPTp). Geneva: 
World Health Organization; 2018.
 68. Gabryszewski SJ, Modchang C, Musset L, Chookajorn T, Fidock DA. 
Combinatorial genetic modeling of pfcrt‑mediated drug resistance 
evolution in Plasmodium falciparum. Mol Biol Evol. 2016;33:1554–70.
 69. Okell LC, Griffin JT, Roper C. Mapping sulphadoxine‑pyrimethamine‑
resistant Plasmodium falciparum malaria in infected humans and in 
parasite populations in Africa. Sci Rep. 2017;7:7389.
 70. Viriyakosol S, Siripoon N, Petcharapirat C, Petcharapirat P, Jarra W, 
Thaithong S, et al. Genotyping of Plasmodium falciparum isolates by 
the polymerase chain reaction and potential uses in epidemiological 
studies. Bull World Health Organ. 1995;73:85–95.
 71. Liljander A, Wiklund L, Falk N, Kweku M, Martensson A, Felger I, et al. 
Optimization and validation of multi‑coloured capillary electrophoresis 
for genotyping of Plasmodium falciparum merozoite surface proteins 
(msp1 and 2). Malar J. 2009;8:78.
 72. Juliano JJ, Taylor SM, Meshnick SR. Polymerase chain reaction 
adjustment in antimalarial trials: molecular malarkey? J Infect Dis. 
2009;200:5–7.
 73. Beshir KB, Diallo N, Sutherland CJ. Identifying recrudescent Plasmodium 
falciparum in treated malaria patients by real‑time PCR and high resolu‑
tion melt analysis of genetic diversity. Sci Rep. 2018;8:10097.
 74. Juliano JJ, Ariey F, Sem R, Tangpukdee N, Krudsood S, Olson C, et al. 
Misclassification of drug failure in Plasmodium falciparum clinical trials 
in southeast Asia. J Infect Dis. 2009;200:624–8.
 75. Su X, Wellems TE. Toward a high‑resolution Plasmodium falciparum 
linkage map: polymorphic markers from hundreds of simple sequence 
repeats. Genomics. 1996;33:430–44.
 76. Anderson TJ, Su XZ, Bockarie M, Lagog M, Day KP. Twelve microsatellite 
markers for characterization of Plasmodium falciparum from finger‑prick 
blood samples. Parasitology. 1999;119(Pt 2):113–25.
 77. Wei G, Zhang L, Yan H, Zhao Y, Hu J, Pan W. Evaluation of the population 
structure and genetic diversity of Plasmodium falciparum in southern 
China. Malar J. 2015;14:283.
 78. Mohd Abd Razak MR, Sastu UR, Norahmad NA, Abdul‑Karim A, Muham‑
mad A, Muniandy PK, et al. Genetic diversity of Plasmodium falciparum 
populations in malaria declining areas of Sabah, East Malaysia. PLoS 
ONE. 2016;11:e0152415.
 79. Nkhoma SC, Nair S, Al‑Saai S, Ashley E, McGready R, Phyo AP, et al. 
Population genetic correlates of declining transmission in a human 
pathogen. Mol Ecol. 2013;22:273–85.
 80. Distefano G, Caruso M, La Malfa S, Gentile A, Wu SB. High resolution 
melting analysis is a more sensitive and effective alternative to gel‑
based platforms in analysis of SSR—an example in citrus. PLoS ONE. 
2012;7:e44202.
 81. Tripathi M, Das A. Genotyping malaria parasites with DNA barcodes. 
Trop Med Int Health. 2015;20:1636–8.
 82. Daniels R, Volkman SK, Milner DA, Mahesh N, Neafsey DE, Park DJ, et al. 
A general SNP‑based molecular barcode for Plasmodium falciparum 
identification and tracking. Malar J. 2008;7:223.
 83. Searle KM, Katowa B, Kobayashi T, Siame MNS, Mharakurwa S, Carpi G, 
et al. Distinct parasite populations infect individuals identified through 
passive and active case detection in a region of declining malaria 
transmission in southern Zambia. Malar J. 2017;16:154.
 84. Obaldia N 3rd, Baro NK, Calzada JE, Santamaria AM, Daniels R, Wong 
W, et al. Clonal outbreak of Plasmodium falciparum infection in eastern 
Panama. J Infect Dis. 2015;211:1087–96.
 85. Campino S, Auburn S, Kivinen K, Zongo I, Ouedraogo JB, Mangano V, 
et al. Population genetic analysis of Plasmodium falciparum parasites 
using a customized Illumina GoldenGate genotyping assay. PLoS ONE. 
2011;6:e20251.
 86. Daniels RF, Schaffner SF, Wenger EA, Proctor JL, Chang HH, Wong W, 
et al. Modeling malaria genomics reveals transmission decline and 
rebound in Senegal. Proc Natl Acad Sci USA. 2015;112:7067–72.
 87. Preston MD, Campino S, Assefa SA, Echeverry DF, Ocholla H, Amambua‑
Ngwa A, et al. A barcode of organellar genome polymorphisms 
identifies the geographic origin of Plasmodium falciparum strains. Nat 
Commun. 2014;5:4052.
 88. Pholwat S, Liu J, Stroup S, Jacob ST, Banura P, Moore CC, et al. The 
malaria TaqMan array card includes 87 assays for Plasmodium falciparum 
drug resistance, identification of species, and genotyping in a single 
reaction. Antimicrob Agents Chemother. 2017;61:e00110–7.
 89. Chang HH, Worby CJ, Yeka A, Nankabirwa J, Kamya MR, Staedke SG, 
et al. THE REAL McCOIL: a method for the concurrent estimation of the 
complexity of infection and SNP allele frequency for malaria parasites. 
PLoS Comput Biol. 2017;13:e1005348.
Page 12 of 12Apinjoh et al. Malar J          (2019) 18:217 
 90. Nag S, Dalgaard MD, Kofoed PE, Ursing J, Crespo M, Andersen LO, et al. 
High throughput resistance profiling of Plasmodium falciparum infec‑
tions based on custom dual indexing and Illumina next generation 
sequencing‑technology. Sci Rep. 2017;7:2398.
 91. Talundzic E, Ndiaye YD, Deme AB, Olsen C, Patel DS, Biliya S, et al. 
Molecular epidemiology of Plasmodium falciparum kelch13 mutations 
in Senegal determined by using targeted amplicon deep sequencing. 
Antimicrob Agents Chemother. 2017;61:e02116‑16.
 92. Anderson TJ, Nair S, McDew‑White M, Cheeseman IH, Nkhoma S, Bilgic 
F, et al. Population parameters underlying an ongoing soft sweep in 
Southeast Asian malaria parasites. Mol Biol Evol. 2017;34:131–44.
 93. Lerch A, Koepfli C, Hofmann NE, Messerli C, Wilcox S, Kattenberg JH, 
et al. Development of amplicon deep sequencing markers and data 
analysis pipeline for genotyping multi‑clonal malaria infections. BMC 
Genomics. 2017;18:864.
 94. Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A, et al. 
Genetic diversity and protective efficacy of the RTS, S/AS01 malaria 
vaccine. N Engl J Med. 2015;373:2025–37.
 95. Lo E, Zhou G, Oo W, Lee MC, Baum E, Felgner PL, et al. Molecular 
inference of sources and spreading patterns of Plasmodium falcipa-
rum malaria parasites in internally displaced persons settlements in 
Myanmar‑China border area. Infect Genet Evol. 2015;33:189–96.
 96. Okombo J, Kamau AW, Marsh K, Sutherland CJ, Ochola‑Oyier LI. Tem‑
poral trends in prevalence of Plasmodium falciparum drug resistance 
alleles over two decades of changing antimalarial policy in coastal 
Kenya. Int J Parasitol Drugs Drug Resist. 2014;4:152–63.
 97. Bousema T, Griffin JT, Sauerwein RW, Smith DL, Churcher TS, Takken 
W, et al. Hitting hotspots: spatial targeting of malaria for control and 
elimination. PLoS Med. 2012;9:e1001165.
 98. Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, et al. 
Reducing Plasmodium falciparum malaria transmission in Africa: 
a model‑based evaluation of intervention strategies. PLoS Med. 
2010;7:e1000324.
 99. Wong W, Griggs AD, Daniels RF, Schaffner SF, Ndiaye D, Bei AK, et al. 
Genetic relatedness analysis reveals the cotransmission of genetically 
related Plasmodium falciparum parasites in Thies, Senegal. Genome 
Med. 2017;9:5.
 100. Ghansah A, Amenga‑Etego L, Amambua‑Ngwa A, Andagalu B, Apinjoh 
T, Bouyou‑Akotet M, et al. Monitoring parasite diversity for malaria 
elimination in sub‑Saharan Africa. Science. 2014;345:1297–8.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
